Shares of Aligos Therapeutics (ALGS) popped on Thursday after the biotech company said it had cut a deal to license its hepatitis B drug candidate in China. Because when you're a clinical-stage biotech firm, sometimes the best way to make money isn't selling a drug—it's selling the rights to sell the drug somewhere else.

The company announced an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus infection in Greater China. That's a region with over 90 million people living with HBV, which is... a lot of potential patients. The deal is contingent on Amoytop getting approval at a shareholders' meeting within 30 days, but assuming that goes through, Aligos gets a nice cash infusion.

Here's how the money works: Aligos gets an upfront milestone payment of $25 million. Then there are potential additional milestones totaling up to $420 million down the road, plus tiered royalties on net sales. All told, that's up to $445 million in milestone payments, not counting the royalties. For a company like Aligos, that kind of deal can be a game-changer—it extends their cash runway into the fourth quarter of 2026, which means more time to run clinical trials without worrying as much about the bank account.

Speaking of clinical trials, let's talk about the drug itself. Pevifoscorvir sodium is currently being evaluated in a Phase 2 study called B-SUPREME, where it's being tested against an existing nucleoside analog called tenofovir disoproxil fumarate. The independent Data Safety Monitoring Review Board looked at the data and recommended increasing the sample size from 74 participants to 100. That's usually a good sign—it means they want more data, not that they're seeing problems.

In fact, the study drugs have shown good tolerability so far, with no clinically concerning lab results, physical exam issues, vital sign abnormalities, or ECG problems. And importantly, there hasn't been any viral breakthrough related to the study drugs to date. The company did a futility analysis, and the results didn't meet the prespecified futility criteria, which is basically a fancy way of saying the trial isn't doomed. The second interim analysis is expected in the second half of 2026, with topline data planned for 2027.

Now, let's look at the stock. Aligos shares were up 9.70% at $8.14 at the time of publication. Over the past year, the stock has returned 62.36%, which is a pretty solid run. Technically, it's trading 13.1% above its 20-day simple moving average, suggesting strong short-term momentum, but it's 2.6% below its 200-day SMA, indicating some longer-term challenges. The relative strength index is at 47.46, which is neutral—neither overbought nor oversold. Key resistance sits at $9.00, and key support is at $8.50. So the stock is kind of in the middle of its range, with room to move in either direction.

What's interesting here is how this deal changes the story for Aligos. They're not just a biotech company running trials anymore—they've got a partner in one of the biggest markets for hepatitis B, and they've bought themselves more time to keep developing their pipeline. For investors, that's a double win: immediate cash and a longer runway.